Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences

Rhea-AI Summary

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced that President and CEO Todd C. Brady, M.D., Ph.D., will participate in analyst-led fireside chats at two upcoming virtual conferences.

• BTIG Virtual Biotechnology Conference
  Date: August 9, 2021, Time: 9:30 a.m. ET
• H.C. Wainwright Ophthalmology Virtual Conference
  Date: August 17, 2021, Time: Available On-Demand from 7:00 a.m. ET

Access details are available on Aldeyra’s Investor & Media page, with archives for 90 days post-event.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will participate in analyst-led fireside conversations at the BTIG Virtual Biotechnology Conference and the H.C. Wainwright Ophthalmology Virtual Conference.

• BTIG Virtual Biotechnology Conference
  Date: Monday, August 9, 2021
  Time: 9:30 a.m. ET

• H.C. Wainwright Ophthalmology Virtual Conference
  Date: Tuesday, August 17, 2021
  Time: Available On-Demand Beginning at 7:00 a.m. ET

To view these events, please visit the Investor & Media page of the company’s website. After the presentations, the events will remain archived on the website for 90 days.

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases. Two of the company’s lead product candidates, reproxalap and ADX-629, target RASP, which are pre-cytokine, systems-based mediators of inflammation. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191 (methotrexate for intravitreal injection), a drug candidate in Phase 3 testing for the prevention of proliferative vitreoretinopathy. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210803005225/en/

FAQ

When will Aldeyra Therapeutics participate in the BTIG Virtual Biotechnology Conference?

Aldeyra Therapeutics will participate in the BTIG Virtual Biotechnology Conference on August 9, 2021, at 9:30 a.m. ET.

What date is the H.C. Wainwright Ophthalmology Virtual Conference for Aldeyra?

The H.C. Wainwright Ophthalmology Virtual Conference for Aldeyra is scheduled for August 17, 2021, and will be available on-demand starting at 7:00 a.m. ET.

Where can I find information about Aldeyra's virtual conference appearances?

Information about Aldeyra's virtual conference appearances can be found on the company's Investor & Media page on their website.

What are the key product candidates of Aldeyra Therapeutics?

Aldeyra's key product candidates include reproxalap and ADX-629, targeting RASP, and ADX-2191 for preventing proliferative vitreoretinopathy.

How long will the conference presentations by Aldeyra be available for viewing?

The conference presentations by Aldeyra will remain archived on their website for 90 days after the events.